Valneva SE

Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.

Filings

160 filings

All Inside information94 Voting rights and capital38 Earnings release12 Threshold crossing5 Quarterly financial information4 Half-year financial report3 Universal registration document2 Annual financial report2

22/07/2026
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
Earnings releaseFR
21/07/2026
Franchissement de seuil
Threshold crossingFrench
21/07/2026
Franchissement de seuil
Threshold crossingFrench
25/06/2026
Valneva Announces Successful Outcome of its Annual General Meeting
Inside informationFR
04/06/2026
Valneva Announces Availability of Documentation for its Annual General Meeting
Inside informationFR
03/06/2026
VALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026
Voting rights and capitalFR
28/05/2026
Valneva to Participate at U.S. and European Investor Conferences in June
Inside informationFR
28/05/2026
Franchissement de seuil
Threshold crossingFrench
13/05/2026
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Quarterly financial informationFR
06/05/2026
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
Earnings releaseFR
05/05/2026
VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026
Voting rights and capitalFR
05/05/2026
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
Earnings releaseFR
30/04/2026
Valneva Announces the Successful Completion of an €84 million Reserved Offering
Inside informationFR
03/04/2026
Declaration of shares and voting rights of Valneva SE – March 2026
Voting rights and capitalFR
26/03/2026
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Inside informationFR
23/03/2026
Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR
Inside informationFrench
18/03/2026
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
Earnings releaseFR
17/03/2026
Document d'enregistrement universel 2025
Universal registration documentFrenchZIP
09/03/2026
Valneva publiera ses résultats financiers consolidés 2025 le 18 mars 2026
Inside informationFrench
09/03/2026
Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
Earnings release
06/03/2026
VALNEVA Declaration of shares and voting rights: February 28, 2026
Voting rights and capitalFR
02/03/2026
Valneva to Participate in Upcoming Investor Conferences
Inside informationFR
19/02/2026
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
Inside information
19/02/2026
Valneva publie son chiffre d’affaires et sa trésorerie non audités pour l’exercice 2025 et fournit ses prévisions pour l’exercice 2026
Earnings releaseFrench
13/02/2026
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom
Inside informationFR
11/02/2026
VALNEVA Declaration of shares and voting rights: January 31, 2026
Voting rights and capitalFR
06/02/2026
VALNEVA Declaration of shares and voting rights: January 31, 2026
Voting rights and capitalFR
03/02/2026
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
Inside informationFR
19/01/2026
Valneva fait un point sur son vaccin contre le chikungunya IXCHIQ®
Inside informationFrench
09/01/2026
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Inside informationFR
08/01/2026
Valneva SE - Declaration of voting rights - December 2025
Voting rights and capitalFR
31/12/2025
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Inside informationFR
10/12/2025
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
Inside informationFR
05/12/2025
VALNEVA Declaration of shares and voting rights: November 30, 2025
Voting rights and capitalFR
26/11/2025
Valneva to Further Consolidate its Operations in France
Inside informationFR
26/11/2025
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
Inside informationFR
20/11/2025
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
Inside informationFR
05/11/2025
VALNEVA Declaration of shares and voting rights: October 31, 2025
Voting rights and capitalFR
04/11/2025
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Inside informationFR
27/10/2025
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Inside informationFR
09/10/2025
Franchissement de seuil
Threshold crossingFrench
09/10/2025
Franchissement de seuil
Threshold crossingFrench
06/10/2025
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
Inside informationFR
06/10/2025
VALNEVA Declaration of shares and voting rights: September 30, 2025
Voting rights and capitalFR
30/09/2025
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
Inside informationFR
03/09/2025
VALNEVA Declaration of shares and voting rights: August 31, 2025
Voting rights and capitalFR

About

ISIN: FR0004056851
Ticker: VLA
LEI: 969500DIVIP5VKNW4948
Sector: Health care
Founded: 1999
Country of registration: FR
Last filing: 22/07/2026, 17:45

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive